Pulse Biosciences (PLSE) Earning Somewhat Favorable Media Coverage, Study Shows
Media stories about Pulse Biosciences (NASDAQ:PLSE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pulse Biosciences earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.6650196219858 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Pulse Biosciences (NASDAQ:PLSE) opened at $24.01 on Thursday. Pulse Biosciences has a 1 year low of $5.20 and a 1 year high of $39.50.
Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.52) earnings per share for the quarter.
About Pulse Biosciences
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.